2,4,6-Trimethyliodobenzene | CAS:4028-63-1

We serve 2,4,6-Trimethyliodobenzene CAS:4028-63-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4,6-Trimethyliodobenzene

Chemical Name:2,4,6-Trimethyliodobenzene
CAS.NO:4028-63-1
Synonyms:2,4,6-Trimethyliodobenzene
2-Iodo-1,3,5-trimethylbenzene
Iodo-2,4,6-trimethylbenzene
2-Iodomesitylene
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 244.9±9.0 °C at 760 mmHg
Melting Point 28-32 °C
Molecular Formula C9H11I
Molecular Weight 246.088
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.584
 
Specification:
Appearance:Yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2,4,6-Trimethyliodobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Iodomesitylene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4,6-Trimethyliodobenzene Use and application,2,4,6-Trimethyliodobenzene technical grade,usp/ep/jp grade.


Related News: ut others aren’t convinced — they think one of the country’s most influential state media outlets could be promoting pseudoscience and false hope.3-Amino-2-methylbenzoic acid manufacturer ut others aren’t convinced — they think one of the country’s most influential state media outlets could be promoting pseudoscience and false hope.Ethanethioic acid S-ethyl ester supplier ut others aren’t convinced — they think one of the country’s most influential state media outlets could be promoting pseudoscience and false hope.2-Bromo-5-fluoropyridine vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.